The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals involved in gene and cell therapy. Founded in 1996, ASGCT's mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. The Society hosts an influential Annual Meeting, publishes leading peer-reviewed journals under the 'Molecular Therapy' family, and actively engages in advocacy, policy development, and public education to support the field's growth and ethical development.
Serves as the central administrative and operational hub for the Society's activities, including membership services, organization of the Annual Meeting and other educational events, advocacy efforts, and management of its publications.
Modern office facilities located within a professional office building, equipped to support the administrative, communication, and collaborative needs of the Society. Specific architectural highlights are not a primary feature.
A mission-driven, professional, and collaborative environment. Staff are dedicated to serving the ASGCT membership and advancing the field of gene and cell therapy through education, advocacy, and fostering scientific exchange.
The headquarters is pivotal for coordinating ASGCT's extensive national and international activities, managing its diverse programs, and serving its global membership base, thus playing a key role in the progress of gene and cell therapies worldwide.
ASGCT fosters a global community of researchers, clinicians, bioindustry professionals, and patient advocates in gene and cell therapy. While its administrative headquarters is in the U.S., its membership is international. ASGCT promotes global collaboration through its renowned Annual Meeting which attracts attendees from around the world, its internationally recognized publications, strategic partnerships with global organizations, and educational initiatives accessible worldwide. The Society actively engages with international regulatory bodies and societies to advance the field and harmonize standards globally.
555 East Wells Street, Suite 1100
Milwaukee
Wisconsin
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, American Society of Gene & Cell Therapy' leadership includes:
American Society of Gene & Cell Therapy has been backed by several prominent investors over the years, including:
In the past 12 months, ASGCT has strategically expanded its executive leadership by appointing its first Chief Financial Officer, significantly enhancing its financial oversight and strategic planning capabilities. The core executive team has otherwise demonstrated stability, continuing to drive the Society's mission forward.
Discover the tools American Society of Gene & Cell Therapy uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
The American Society of Gene & Cell Therapy (ASGCT) typically utilizes a standardized email format for its staff, most commonly combining the first initial and last name of the employee with the organization's domain, asgct.org.
[first_initial][last]@asgct.org
Format
dbarrett@asgct.org
Example
70%
Success rate
asgct.org • April 2, 2024
ASGCT announced the recipients of its prestigious 2024 awards, recognizing individuals for their outstanding contributions to the field of gene and cell therapy. The awards are scheduled to be presented at the ASGCT 27th Annual Meeting....more
asgct.org • January 10, 2024
The American Society of Gene & Cell Therapy (ASGCT) announced the appointment of Phillip Le, MBA, as its first Chief Financial Officer. Le brings over 20 years of financial leadership experience to guide the Society's financial strategy and operations....more
asgct.org • December 8, 2023
ASGCT commended the U.S. Food and Drug Administration's (FDA) landmark approval of Casgevy and Lyfgenia, the first two CRISPR-based gene therapies for treating sickle cell disease in patients aged 12 and older, marking a significant advancement in the field....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including American Society of Gene & Cell Therapy, are just a search away.